Sai Life Sciences Ltd Q4 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Published 6 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹29.6K Cr
Sai Life Sciences targets long-term revenue growth of 15% to 20% over a 3 to 5-year period. Sai Life Sciences targets long-term revenue growth of 15%-20% over a 3-5 year period, reflecting industry cyclicality and pipeline visibility.
From Sai Life Sciences Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Price
₹1,457
Market Cap
₹29.6K Cr
P/E Ratio
83.4
How does Sai Life Sciences Ltd rank in Pharmaceuticals & Biotechnology?
Compare Sai Life Sciences Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Sai Life Sciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹602 Cr, net profit ₹104 Cr.
Full financials →📊 Revenue & Sales Performance
- →Sai Life Sciences targets long-term revenue growth of 15% to 20% over a 3 to 5-year period.
- →The company plans to achieve EBITDA margins of 28% to 30% within the next couple of years.
- →Revenue growth reflects strong momentum across CDMO and CRO businesses, supported by molecule pipeline scaling up and commercial product volume increases.
- →FY25 revenue grew 16% YoY, with FY26 expected to continue strong growth momentum and improve from 25% EBITDA margin in FY25 to 28%-30% in next 2 years.
- →Capex of about INR700 crores planned for FY26 focused 60-65% on manufacturing and 35% on R&D to support FY27 growth.
- →Supply chain shifts favoring India and expanded capacity by 30% expected to support volume growth.
- →The business remains cyclical with potential volatility, but balanced across discovery, development, and commercial segments to sustain growth.
📈 Profitability & Margins
- →Sai Life Sciences targets long-term revenue growth of 15%-20% over a 3-5 year period, reflecting industry cyclicality and pipeline visibility.
- →EBITDA margin guidance is maintained at 28%-30% within the next couple of years.
- →Profit after tax (PAT) for FY25 showed a strong 105% year-on-year increase, supported by operating leverage and cost efficiencies.
- →Return on capital employed (ROCE) is targeted in the mid-to-high teen range as committed during the IPO.
- →The company anticipates increasing capacity utilization and improving operational performance, which support future margin expansion.
- →Capex investments of around INR 700 crores for FY26 aim to support growth beyond fiscal year 2027.
- →Earnings growth may be lumpy due to the cyclical nature of the CDMO industry and timing of commercial product launches.
🏗️ Capital Expenditure Plans
- →For FY26, Sai Life Sciences plans capex of close to INR 700 crores.
- →Approximately INR 550 crores of this capex is currently planned based on existing visibility, primarily to support fiscal '27 growth.
- →INR 50 to 70 crores of capex is earmarked for new modalities including peptides, ADCs, and oligonucleotides.
- →The remaining balance capex will be triggered based on business visibility throughout the year.
- →Around 60% to 65% of capex will be directed toward manufacturing, and 35% toward R&D.
- →Maintenance capex is roughly INR 70 crores.
- →New manufacturing capacities came online in November and May, increasing capacity by about 30%.
- →Capex funding will come from internal accruals, debt, and residual IPO proceeds.
- →Investments aim to support pipeline scaling, process development, and expand discovery and manufacturing capabilities.
💰 Fundraising & Capital Structure
- →Sai Life Sciences plans to fund its capex of around INR 700 crores for FY26 through a combination of internal accruals, debt, and remaining funds from the IPO process.
- →There is no specific mention of new equity fundraising; the company intends to utilize the IPO proceeds still available.
- →Debt repayment of INR 720 crores was completed as part of the IPO funds, significantly reducing leverage.
- →Lower interest costs are expected from FY26 due to this reduced leverage.
- →The company balances funding between internal cash flows and debt but has not announced plans for fresh equity issuance.
📋 Order Book & Pipeline
- →Sai Life Sciences sees strong visibility and increased client flow supporting growth despite a softer global CRDMO environment. (Page 15)
- →Demand is driven primarily by supply chain shifts and long-standing client relationships. (Page 15)
- →The company has observed significant traction in both process development and manufacturing with several molecules scaling up, which is fueling capex expansion. (Pages 9, 10, 15)
- →Current manufacturing capacity utilization is high (~67% in FY25) with a 30% capacity increase expected from new lines coming online between November and May. (Page 6)
- →The pipeline shows some molecules in late-phase commercial stages; however, exact commercial launch timings are uncertain and out of CDMO control. (Page 10)
- →While specific orderbook numbers are not disclosed, the company expresses confidence in sustained pipeline demand and visibility over the next year. (Pages 6, 9, 10, 15)
Key Metrics
Frequently Asked Questions
What were Sai Life Sciences Ltd Q4 FY25 results?
Sai Life Sciences targets long-term revenue growth of 15% to 20% over a 3 to 5-year period. Sai Life Sciences targets long-term revenue growth of 15%-20% over a 3-5 year period, reflecting industry cyclicality and pipeline visibility.
What is Sai Life Sciences Ltd share price analysis?
Sai Life Sciences Ltd currently shows a neutral. The stock trades at a P/E of 83.4 with a market cap of ₹29,600 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sai Life Sciences Ltd planning capital expenditure?
For FY26, Sai Life Sciences plans capex of close to INR 700 crores.
Keep Sai Life Sciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.